About

Published Works

crochan o'sullivan outside dublin clinic

Original Articles

  1. O’Sullivan CJ, Montalbetti M, Zbinden R, Kurz DJ, Bernheim AM, Liew A, Meyer MR, Tüller D, Eberli FR. Screening for pulmonary hypertension with multidetector computed tomography among patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Front Cardiovasc Med. 2018.5;5:63. PMID:29951486.
  2. Pilgrim T, Lee JKT, O’Sullivan CJ, Stortecky S, Ariotti S, Franzone A, Lanz J, Heg D, Asami M, Praz F, Siontis GCM, Vollenbroich R, Räber L, Valgimigli M, Roost E, Windecker S. Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis. Open Heart. 2018 Jan 20;5(1):e000695. PMID 29387427.
  3. Yamaji K, Ueki Y, Souteyrand G, Daemen J, Wiebe J, Nef H, Adriaenssens T, Loh JP, Lattuca B, Wykrzykowska JJ, Gomez-Lara J, Timmers L, Motreff P, Hoppmann P, Abdel-Wahab M, Byrne RA, Meincke F, Boeder N, Honton B, O’Sullivan CJ, Lelasi A, Delarche N, Christ G, Lee JKT, Lee M, Amabile N, Karagiannis A, Windecker S, Räber L. Mechanisms of Very Late Bioresorbable Scaffold Thrombosis: The INVEST Registry. J Am Coll Cardiol. 2017;70(19):2330-2344. PMID: 29096803.
  4. Franzone A, O’Sullivan CJ, Stortecky S, Heg D, Lanz J, Vollenbroich R, Praz F, Piccolo R, Asami M, Roost E, Räber L, Vlalgimigli M, Windecker S, Pilgrim T. Prognostic impact of invasive haemodynamic measurements in combination ith clinical and echocardiographic characteristics on two-year clinical outcomes of patients undergoing transcatheter aortic valve implantation. EuroIntervention 2017;12(18):e2186-e2193. PMID:28117283.
  5. Vollenbroich R, Stortecky S, Praz F, Lanz J, Franzone A, Zuk K, Heg D, Valgimigli M, O’Sullivan CJ, Heinisch C, Roost E, Wenaweser P, Windecker S, Pilgrim T. The impact of functional vs degererative mitral regurgitation on clinical outcomes among patients undergoing transcatheter aortic valve implantation. Am Heart J. 2017;184:71-80. PMID:27892889.
  6. O’Sullivan CJ, Spitzer E, Heg D, Praz F, Stortecky S, Huber C, Carrel T, Pilgrim T, Windecker S. Effect of resting heart rate on two-year clinical outcomes of high-risk patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve implantation. EuroIntervention 2016;12(4):490-8. PMID:27436601.
  7. Koskinas KC, Stortecky S, Franzone A, O’Sullivan CJ, Praz F, Zuk K, Räber L, Pilgrim T, Moschovitis A, Fiedler GM, Jüni P, Heg D, Wenaweser P, Windecker S. Post-procedural troponin elevation and clinical outcomes following transcatheter aortic valve implantation. J Am Heart Assoc. 2016;5(2):e002430. PMID:26896474.
  8. Räber L, Brugaletta S, Yamaji K, O’Sullivan CJ, Otsuki S, Kopara T, Taniwaki M, Onuma Y, Freixa X, Eberli FR, Serruys PW, Joner M, Sabatè M, Windecker S. Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol. 2015;66(17):1901-14. PMID:26493663.
  9. Koskinas KC, O’Sullivan CJ, Heg D, Praz F, Stortecky S, Pilgrim T, Buellesfeld L, Jüni P, Windecker S, Wenaweser P. Effect of B-type natriuretic peptides on long-term outcomes after transcatheter aortic valve implantation. Am J Cardiol. 2015;116(10):1560-5. PMID:26428025.
  10. O’Sullivan CJ, Wenaweser P, Ceylan O, Rat-Wirtzler J, Stortecky S, Heg D, Spitzer E, Zanchin T, Praz F, Tüller D, Huber C, Pilgrim T, Nietlispach F, Khattab AA, Carrel T, Meier B, Windecker S, Buellesfeld L. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv. 2015;8(7):e002358. PMID:26156149.
  11. O’Sullivan CJ, Englberger L, Hosek N, Heg D, Cao D, Stefanini GG, Stortecky S, Gloekler S, Spitzer E, Tüller D, Huber C, Pilgrim T, Praz F, Buellesfeld L, Khattab AA, Carrel T, Meier B, Windecker S, Wenaweser P. Clinical outcomes and revascularization strategies in patients with low-flow, low-gradient severe aortic valve stenosis according to the assigned treatment modality. JACC Cardiovasc Interv. 201;8(5):704-17. PMID:25946444.
  12. Huber C, Praz F, O’Sullivan CJ, Langhammer B, Gloekler S, Stortecky S, von Allmen RS, Meier B, Carrel T, Englberger L, Windecker S, Wenaweser P. Transcarotid aortic valve-in-valve implantation for degenerated stentless aortic root conduits with severe regurgitation: a case series. Interact Cardiovasc Thorac Surg. 2015;20(6):694-700. PMID:25776924.
  13. O’Sullivan CJ, Stortecky S, Bütikofer A, Heg D, Zanchin T, Huber C, Pilgrim T, Praz F, Buellesfeld L, Khattab AA, Blöchlinger S, Carrel T, Meier B, Zbinden S, Wenaweser P, Windecker S. Impact of mitral regurgitation on clinical outcomes of patients with low-ejection fraction, low-gradient severe aortic stenosis undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2015;8(2):e001895. PMID:25657315.
  14. Mylotte D, Lefevre T, Sondergaard L, Wantanabe Y, Modine T, Dvir D, Bosmans J, Tchetche D, Kornowski R, Sinning JM, Thèriault-Lauzier P, O’Sullivan CJ, Barbanti M, Debry N, Buithieu J, Codner P, Dorfmeister M, Martucci G, Nickenig G, Wenaweser P, Tamburino C, Grube E, Webb JG, Windecker S, Lange R, Piazza N. J Am Coll Cardiol. 2014;64(22):2330-9. PMID:5465419.
  15. Rothenbühler M, O’Sullivan CJ, Stortecky S, Stefanini GG, Spitzer E, Estill J, Shrestha NR, Keiser O, Jüni P, Pilgrim T. Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents. Lancet Glob Health. 2014;2(12):e717-26. PMID:25433627.
  16. Pilgrim T, Englberger L, Rothenbühler M, Stortecky S, Ceylan O, O’Sullivan CJ, Huber C, Praz F, Buellesfeld L, Langhammer B, Meier B, Jüni P, Carrel T, Windecker S, Wenaweser P. Long-term outcome of elderly patients with severe aortic stenosis as a function of treatment modality. Heart 2015;101(1):30-6. PMID:25163691.
  17. Khattab AA, Gloekler S, Sprecher B, Shakir S, Guerios E, Stortecky S, O’Sullivan CJ, Nietlispach F, Moschovitis A, Pilgrim T, Buelesfeld L, Wenaweser P, Windecker S, Meier B. Feasibility and outcomes of combined transcatheter aortic valve replacement with other structural heart interventions in a single session: a matched cohort study. Open Heart 2014;1(1):e000014. PMID:25332781.
  18. Stefanini GG, Stortecky S, Cao D, Rat-Wirtzler J, O’Sullivan CJ, Gloekler S, Buellesfeld L, Khattab AA, Nietlispach F, Pilgrim T, Huber C, Carrel T, Meier B, Jüni P, Wenaweser P, Windecker S. Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation. Eur Heart J. 2014;35(37):2530-40. PMID:24682843.
  19. O’Sullivan CJ, Stortecky S, Heg D, Jüni P, Windecker S, Wenaweser P. Impact of B-type natriuretic peptide on short-term clinical outcomes following transcatheter aortic valve implantation. EuroIntervention. 2015;10(10):e1-8. PMID:24429160.
  20. O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical Outcomes Of Patients with Low Flow, Low Gradient, Severe Aortic Stenosis and Either Preserved or Reduced Ejection Fraction Undergoing Transcatheter Aortic Valve Implantation. Eur Heart J. 2013;Nov;34(44):3437-50. PMID:24096324
  21. O’Sullivan CJ, Stefanini GG, Räber L, Heg D, Taniwaki M, Kalesan B, Pilgrim T, Zanchin T, Moschovitis A, Büllesfeld L, Khattab AA, Meier B, Wenaweser P, Jüni P, Windecker S. Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug eluting stents. EuroIntervention 2014;9(9):1076-84. PMID:24064474.
  22. Wenaweser P, Stortecky S, Schwander S, Heg D, Huber C, Pilgrim T, Gloekler S, O’Sullivan CJ, Meier B, Jüni P, Carrel T, Windecker S. Clinical Outcomes of Patients with Estimated Low or Intermediate Surgical Risk Undergoing Transcatheter Aortic Valve Implantation. Eur Heart J. 2013 Jul;34(25):1894-905. PMID:23487519.
  23. Khattab AA, O’Sullivan CJ, Stefanini GG, Räber L, Paquin M, Windecker S, Meier B. New Approach to Direct Stenting using a Novel ‘All-In-One’ Coronary Stent System via 5 French Diagnostic Catheters: A Pilot Study. Catheter Cardiovasc Interv. 2013;82(4):E403-10.  PMID:23378279.
  24. Doyle BJ, Rihal CS, O’Sullivan CJ, Lennon RJ, Wiste HJ, Bell M, Bresnahan J, Holmes DR. Outcomes of Stent Thrombosis and Restenosis during Extended Follow Up of Patients Treated with Bare-Metal Coronary Stents. Circulation. 2007;116:2391-2398. PMID:17984377.
  25. O’Sullivan CJ, Hynes N, Mahendran M, Andrews EJ, Avalos G, Tawfik S, Sultan S. Haemoglobin A1c (HbA1c) in Non-diabetic and Diabetic Vascular Patients. Is HbA1c an Independent Risk Factor and Predictor of Adverse Outcome? European Journal of Vascular and Endovascular Surgery. 2006 Aug;32(2):188-197. PMID:16580235.
  26. O’Loughlin AJ, O’Sullivan CJ, Ravikumar N, Friel AM, Elliott JT, Morrison JJ. Effects of Thrombin, PAR-1 Activating Peptide and a PAR-1 Antagonist on Umbilical Artery Resistance in vitro. Reproductive Biology and Endocrinology. 2005 Feb 24;3(1):8. PMID:15730558.
  27. O’Sullivan CJ, Allen NM, O’Loughlin AJ, Friel AM, Morrison JJ. Thrombin and PAR1-Activating Peptide: Effects on Human Uterine Contractility in vitro.
    American Journal of Obstetrics and Gynecology. 2004 Apr;190(4):1098-105. PMID:15118649

Review Articles

  1. O’Sullivan CJ, Wenaweser P. A glimpse into the future: In 2020, which patients will undergo TAVI or SAVR? Interventional Cardiology Review. 2017;12(1):44-50.
  2. O’Sullivan CJ, Tüller D, Zbinden R, Eberli FR. Impact of mitral regurgitation on clinical outcomes after transcatheter aortic valve implantation. Interventional Cardiology Review. 2016;11(1):54-8.
  3. O’Sullivan CJ, Wenaweser P. Optimizing clinical outcomes of transcatheter aortic valve implantation patients with comorbidities. Expert Rev Cardiovasc Ther. 2015;13(12):1419-32. PMID:26479904.
  4. O’Sullivan CJ, Stefanini GG, Stortecky S, Tüller D, Windecker S, Wenaweser P. Coronary revascularization and TAVI: before, during, after or never? Minerva Med. 2014;105(6):475-85. PMID:25274461.
  5. O’Sullivan CJ, Praz F, Stortecky S, Windecker S, Wenaweser P. Assessment of low-flow, low-gradient, severe aortic stenosis: an invasive evaluation is required for decision making. EuroIntervention. 2014;10 Suppl U:U61-8. PMID:25256333.
  6. O’Sullivan CJ, Stortecky S, Buellesfeld L, Wenaweser P, Windecker S. Preinterventional Screening of the TAVI Patient: How to Choose the Suitable Patient and the Best Procedure. Clinical Research in Cardiology. 2014:103(4):259-74. PMID 24515650.
  7. Stortecky S, O’Sullivan CJ, Buellesfeld L, Wenaweser P, Windecker S. Transcatheter Aortic Valve Implantation: Patient Selection.
    Minerva Cardioangiologica. 2013 Oct;61(5):487-497. PMID: 24096244
  8. Stortecky S, O’Sullivan CJ, Buellesfeld L, Windecker S, Wenaweser P. Transcatheter Aortic Valve Implantation: The Transfemoral Access Route is the Default Access. EuroIntervention. 2013 Sep 10;9 Suppl:S14-8. PMID:24025952

Editorials

  1. O’Sullivan CJ, Spitzer E. Transaortic flow rate versus stroke volume index in low-gradient aortic stenosis. JACC: Cardiovascular Imaging 2018. In Press.
  2. O’Sullivan CJ, Wenaweser P. Can we predict quality of life and survival after transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2015;8(12):e003347. PMID:26643742.
  3. O’Sullivan CJ, Eberli FR. Left ventricular thrombus formation after acute myocardial infarction. Vigilance still required in the modern era. Swiss Med Wkly. 2015;145:w14158. PMID:26099039.
  4. O’Sullivan CJ, Wenaweser P. Reclassification of low-gradient aortic stenosis severity in patients with preserved ejection fraction: when is severe truly severe? Eur Heart J.2015;36(31):2039-2041. PMID:26040798.
  5. O’Sullivan CJ, Wenaweser P. Low-flow, low-gradient aortic stenosis: should TAVI be the default therapeutic option? EuroIntervention. 2014;10(7):775-7. PMID:25414144.
  6. Windecker S, O’Sullivan CJ. Mitigating the risk of early stent thrombosis.
    J Am Coll Cardiol. 2014;63(23):2521-4. PMID:24768885.
  7. O’Sullivan CJ, Windecker S. Implications of Bicuspid Aortic Valves for Transcatheter Aortic Valve Implantation. Circ Cardiovasc Interv. 2013;6(3):204-6. PMID:23780294.
  8. O’Sullivan CJ, Windecker S. Peri-procedural myocardial infarction: time for re-evaluation of its definition and use as an endpoint in coronary stent trials.
    Heart. 2012;98(19):1397-1399. PMID:22965793.
  9. O’Sullivan CJ, Wenaweser P. Aortic stenosis and the right heart at risk: Is transcatheter aortic valve implantation the better option? Heart. 2012;98(17):1265-6. PMID:22875821.

Case Reports

  1. O’Sullivan CJ, Groza D, Eberli FR. Left ventricular pseudoaneurysm formation in a patient presenting with a subacute myocardial infarction. BMJ Case Report. 2017;pii: bcr-2017-222481. doi: 10.1136/bcr-2017-222481. PMID 29246934
  2. O’Sullivan CJ, Kurz DJ. An unusual cause of cardiac tamponade following pericardial window formation. Acta Cardiologica. 2017
  3. O’Sullivan CJ, Magarzo JG, Bernheim AM, Eberli FR. Paradoxical embolism via a sinus venosus atrial septal defect causing an inferior ST-segment elevation myocardial infarction in a 23-year-old woman. BMJ Case Rep. 2016;pii:bcr2016215184. PMID: 27130557.
  4. O’Sullivan CJ, Bühlmann Lerjen E, Pellegrini D, Eberli FR. Sudden cardiac arrest during emergency caesarean delivery in a 31-year-old woman, due to accelerated structural valve degeneration of an aortic valve bioprosthesis. BMJ Case Rep. 2015. Pii:bcr2015212575. PMID:26568057.
  5. O’Sullivan CJ, Sprenger M, Tueller D, Eberli FR. Coronary thromboembolic acute myocardial infarction due to paroxysmal atrial fibrillation occurring after non-cardiac surgery. BMJ Case Rep. 2015;2015.pii:bcr2014208329. PMID:25814175.
  6. O’Sullivan CJ, Meier B. Left Main Coronary Stent Positioning using Rapid Transcoronary Pacing. Journal of Invasive Cardiology 2013 Jan;25(1):E4-7.PMID:23293185.

Letters to the Editor

  1. O’Sullivan CJ, Wenaweser P, Ceylan O, Stortecky S, Spitzer E, Zanchin T, Praz F, Pilgrim T, Khattab AA, Meier B, Windecker S, Buellesfeld L, Tüller D, Rat-Wirtzler J, Heg D, Huber C, Carrel T, Nietlispach F. Response to letter regarding article, „Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: Insights from the new proposed pulmonary hypertension classification“. Circ Cardiovasc Interv. 2015;8(9):e003064. PMID:26330389.
  2. O’Sullivan CJ, Stortecky S, Wenaweser P. Invasive Hemodynamic Characteristics of Paradoxical Low Flow, Low Gradient Aortic Stenosis.
    J Am Coll Cardiol 2013 Oct 15;62(16):1492-1493. PMID:23892253

Book Chapters

  1. O’Sullivan CJ, Meier B. Transcoronary Pacing. Urgent Interventional Therapies. Kipshidze N, Fareed J, Rosen RT, Serruys P. October 2014, Wiley-Blackhall. ISBN: 978-0-470-67202-0.

Abstracts

  1. O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical outcomes among patients with low flow, low gradient, severe aortic stenosis according to treatment modality. J Am Coll Cardiol 2013;62(18_S1):B217-B217
  2. O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical Outcomes among patients with low-flow, low-gradient, severe aortic stenosis with either preserved or reduced ejection fraction undergoing transcatheter aortic valve replacement. Ir J Med Sci 2013;182(Suppl 8):S359-S392.
  3. O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical outcomes among patients with low flow, low gradient, severe aortic stenosis according to treatment modality. EuroIntervention Supplement 2013;9 London abstracts.
  4. O’Sullivan CJ, Stortecky S, Hosek N, Ceylan O, Gloekler S, Büllesfeld L, Meier B, Windecker S, Wenaweser P. Impact of B-type natriuretic peptide on clinical outcomes among patients undergoing transcatheter aortic valve implantation. European Heart Journal 2013;34(Suppl 1):993
  5. O’Sullivan C, Stortecky S, Hosek N, Huber C, Pilgrim T, Khattab A, Gloekler S, Nietlispach F, Buellesfeld L, Meier B, Carrel T, Windecker S, Wenaweser P. Prevalence, invasive haemodynamic characteristics and clinical outcomes of patients with “paradoxical” low flow, low gradient severe aortic stenosis with preserved ejection fraction undergoing TAVI. EuroIntervention Supplement 2013:139.
  6. Steffanini GG, Taniwaki M, Räber L, Cao D, Pilgrim T, Stortecky S, O’Sullivan CJ, Wenaweser P, Meier B, Jüni P, Windecker S. Stent thrombosis with zotarolimus-eluting resolute stents compared with everolimus-eluting stents: an updated meta-analysis of randomised clinical trials. EuroIntervention Supplement 2013:98.
  7. O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical Outcomes among patients with low-flow, low-gradient, severe aortic stenosis with either preserved or reduced ejection fraction undergoing transcatheter aortic valve replacement: An invasive hemodynamic study. J Am Coll Cardiol. 2013;61(10):A495
  8. O’Sullivan CJ, Stefanini G, Räber L, Heg D, Taniwaki M, Kalesan B, Pilgrim T, Zanchin T, Moschovitis A, Büllesfeld L, Khattab AA, Wanaweser P, Meier B, Jüni P, Windecker S. Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents. J Am Coll Cardiol. 2012;60(17):B175
  9. O’Sullivan CJ, Moschovitis A, Zanchin T, Stortecky S, Stefanini G, Pilgrim T, Räber L, Taniwaki M, Büllesfeld L, Khattab A, Nietlispach F, Wenaweser PM, Meier B, Windecker S. Long-term clinical outcomes of percutaneous coronary intervention with drug-eluting stents in patients with mechanical heart valves. Cardiovascular Medicine 2012;15(5):Suppl 21:43
  10. O’Sullivan CJ, Andrews EJ, Mahendran B, Hynes N, Avalos G, Tawfik S, Lowery A, Sultan S. Is HbA1c an independent risk factor and predictor of adverse outcome in diabetic and non-diabetic vascular patients? Irish Journal of Medical Science January, February, March 2006:175(1)S2:34
  11. O’Sullivan CJ, Hynes N, Mahendran M, Tawfik S, Tawfik W, Courtney D, Sultan S. HbA1c as an independent risk factor and predictor of adverse outcome in diabetic and non-diabetic vascular patients: A prospective cross-over study with primary composite end-point. Irish Journal of Medical Science January, February, March 2006:175(1)S1:16.
  12. O’Sullivan CJ, Sultan S, Andrews E, Hynes N, Mahendran M, Ishtiaq A, Courtney D. Haemoglobin A1C (HBA1C) in nondiabetic vascular patients. Is HBA1C an independent risk factor and predictor of adverse outcome? European Society for Vascular Surgery, Programme and Abstract Book, September 2005: page 94.
  13. O’Sullivan CJ, Andrews E, Mahendran M, Hynes N, Ishtiaq A, Sultan S. Haemaoglobin A1c (HbA1c) in nondiabetic vascular patients. Is HbA1c an independent risk factor and predictor of adverse outcome? Irish Journal of Medical Science September 2005:174(3)S1:49.
  14. O’Sullivan CJ,  Andrews E, Mahendran M, Hynes N, Ishtiaq A, Sultan S. Haemoglobin A1C (HbA1c) in nondiabetic vascular patients is an independent risk factor and predictor of adverse outcome. A cohort study. Vascular Annual Meeting Chicago, IL, Scientific Program, June 2005: page 74.
  15. O’Sullivan CJ, O’Loughlin AJ, Friel AM, Elliot JT, Morrison JJ. PAR function in the human pregnant myometrium: Effects of Thrombin and Specific PAR-1 Agonist and Antagonist. Journal of the Society for Gynecologic Investigation March 2003:10(2)299A.
  16. O’Loughlin AJ, O’Sullivan CJ, Ravikumar N, Friel AM, Elliot JT, Morrison JJ. Effects of Thrombin, PAR-1 Agonist, and PAR-1 Antagonist on Umbilical Artery Resistance in vitro. Journal of the Society for Gynecologic Investigation March 2003:10(2)299A.
  17. O’Sullivan CJ, Allen NM, O’Loughlin AJ, Friel AM, Elliot JT, Morrison JJ. PAR Function in Human Pregnant Myometrium: Effects of Thrombin and Specific PAR-1 Agonist and Antagonist. British Journal of Obstetrics and Gynecology 2003 Oct;110(10):962.
  18. O’Sullivan CJ, O’Loughlin AJ, Friel AM, Elliot JT, Morrison JJ. PAR function in the human pregnant myometrium: Effects of Thrombin and Specific PAR-1 Agonist and Antagonist. Galway Medical Annual 2003.

Presentations

London, United Kingdom. PCR London Valves 2013. O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical outcomes among patients with low flow, low gradient, severe aortic stenosis according to treatment modality (Oral presentation).

Amsterdam, Netherlands. European Society of Cardiology 2013. O’Sullivan CJ, Stortecky S, Hosek N, Ceylan O, Gloekler S, Büllesfeld L, Meier B, Windecker S, Wenaweser P. Impact of B-type natriuretic peptide on clinical outcomes among patients undergoing transcatheter aortic valve implantation (Poster presentation)

Paris, France. EuroPCR 2013. O’Sullivan C, Stortecky S, Hosek N, Huber C, Pilgrim T, Khattab A, Gloekler S, Nietlispach F, Buellesfeld L, Meier B, Carrel T, Windecker S, Wenaweser P. Prevalence, invasive haemodynamic characteristics and clinical outcomes of patients with “paradoxical” low flow, low gradient severe aortic stenosis with preserved ejection fraction undergoing TAVI (Oral Presentation).

San Francisco, USA (March 9-11, 2013) American College of Cardiology 2013 annual meeting. O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Zanchin T, Hosek N, Gloekler S, Meier B, Windecker S, Wenaweser P. Clinical Outcomes among patients with low-flow, low-gradient, severe aortic stenosis with either preserved or reduced ejection fraction undergoing transcatheter aortic valve replacement: An invasive hemodynamic study (Oral presentation).

Miami, USA (October 22-26, 2012) Transcatheter Cardiovascular Therapeutics Meeting: O’Sullivan CJ, Stefanini G, Räber L, Heg D, Taniwaki M, Kalesan B, Pilgrim T, Zanchin T, Moschovitis A, Büllesfeld L, Khattab AA, Wanaweser P, Meier B, Jüni P, Windecker S. Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents (TCT-605) (Poster)

Lausanne, Switzerland (June 2012) Swiss Cardiology Society: . Long-term Clinical Outcomes of Percutaneous Coronary Intervention with Drug-Eluting Stents in Patients with Mechanical Heart Valves (Oral presentation)

San Francisco, USA (November 7-11, 2011) Transcatheter Cardiovascular Therapeutics Meeting: O’Sullivan CJ et al. Which is the Culprit? Complex Revascularization in a 63-Year-Old Male with Previous Coronary Artery Bypass Grafting Presenting with Non-ST-Segment Elevation Myocardial Infarction (TCT-1012) (presented in the Challenging Cases Video Abstracts section)

Paris, France (May 17-20, 2011) EuroPCR: O’Sullivan CJ et al. The Coronary Guide Wire Won’t Come Back. (Presented in the Interactive Case Corner Section).

Helsinki, Finland (September 16-19, 2005): European Society for Vascular Surgery (ESVS) 19th Annual Meeting. O’Sullivan CJ, Sultan S, Andrews E, Hynes N, Mahendran M, Ishtiaq A, Courtney D. Haemoglobin A1C (HBA1C) in nondiabetic vascular patients. Is HBA1C an independent risk factor and predictor of adverse outcome? (Short-listed for Prize)

Chicago, Illinois, US (June 16-19, 2005): Society of Vascular Surgery (SVS) 2005 Annual Meeting. O’Sullivan CJ, Andrews E, Mahendran M, Hynes N, Istiaq A, Sultan S. Haemoglobin A1c (HbA1c) in nondiabetic and diabetic vascular patients is an independent risk factor and predictor of adverse outcome. A cohort study.

Berlin, Germany (June 3-4, 2005): Vascular Biology Working Group European Chapter Meeting. O’Sullivan CJ, Mahendran M, Sultan S. Haemoglobin A1c (HbA1c) in non-diabetic and diabetic vascular patients. Is HbA1c an independent risk factor and predictor of adverse outcome?

Glasgow, Scotland, UK (June 4-5, 2003): Combined Blair Bell/Munro-Kerr Society Meeting, Glasgow Royal Infirmary. O’Sullivan CJ,Allen NM, O’Loughlin AJ, Friel AM, Elliot JT, Morrison JJ. PAR Function in the Human Pregnant Myometrium: Effects of Thrombin and Specific PAR-1 Agonist and Antagonist.

Washington DC, US (March 25-30, 2003): 50th Anniversary Meeting of the Society for Gynecologic Investigation (SGI). O’Sullivan CJ, O’Loughlin AJ, Friel AM, Elliot JT, Morrison JJ. PAR function in the human pregnant myometrium: Effects of Thrombin and Specific PAR-1 Agonist and Antagonist.

crochan o'sullivan giving presentation